Quick answer: latest quarter results, by ticker or company name

Reported Q: Q3 2024 Rev YoY: -16.2% EPS YoY: -22.0% Move: +13.48%

Modern Chinese Medicine

1643.HK

HKD1.010 13.48%

Exchange HKSE Sector Healthcare Industry Drug Manufacturers General

Q3 2024

Published: Sep 30, 2024

Company Status Snapshot

Fast view of the latest quarter outcome for 1643.HK

Reported

Report Date

Sep 30, 2024

Quarter Q3 2024

Revenue

68.72M

YoY: -16.2%

EPS

0.01

YoY: -22.0%

Market Move

+13.48%

Previous quarter: N/A

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

Revenue of $68.72M down 16.2% year-over-year
EPS of $0.01 decreased by 22% from previous year
Gross margin of 24.4%
Net income of 8.26M
"N/A" - N/A

1643.HK

Company 1643.HK

Period Q3 2024

Currency CNY

Report Type Quarterly Earnings

Generated Feb 10, 2026

Executive Summary

Modern Chinese Medicine Group delivered a profitable Q3 2024, with revenue of 68.72 million CNY, down 16.18% year‑over‑year but up 79.37% quarter‑over‑quarter, reflecting a volatile topline basis yet favorable quarterly seasonality. Gross profit was 16.75 million CNY, yielding a gross margin of 24.37%, while operating income reached 9.12 million CNY for an operating margin of 13.27%. Net income stood at 8.26 million CNY (net margin 12.02%), and EPS was 0.0138 CNY. EBITDA was 11.38 million CNY (EBITDA margin ~16.55%). The quarter underscored a resilient profitability profile amid a smaller base, driven by a disciplined cost structure and a stable gross margin.

Key Performance Indicators

Revenue

Decreasing

68.72M

QoQ: 79.37% | YoY: -16.18%

Gross Profit

Decreasing

16.75M

24.37% margin

QoQ: 54.33% | YoY: -25.48%

Operating Income

Decreasing

9.12M

QoQ: 346.61% | YoY: -29.22%

Net Income

Decreasing

8.26M

QoQ: 341.13% | YoY: -22.12%

EPS

Decreasing

0.01

QoQ: 342.11% | YoY: -22.03%

Revenue Trend

Margin Analysis

Financial Highlights

Revenue: 68.72m CNY (YoY -16.18%, QoQ +79.37%). Gross Profit: 16.75m CNY (Gross Margin 24.37%). Operating Income: 9.12m CNY (Operating Margin 13.27%). Net Income: 8.26m CNY (Net Margin 12.02%). EPS: 0.0138 CNY. EBITDA: 11.38m CNY (EBITDA Margin 16.55%). Balance Sheet: Total assets 540.31m, cash and equivalents 229.67m, total liabilities 56.08m, equity 484.23m. Liquidity: Current ratio 7.20, quick ratio 6.58, cash ratio 4.69. Cash flow: Operating cash flow -7.69m CNY, free cash flow -7.64m CNY. Leverage: Net debt position -229.53m CNY (net cash). Valuation snapshot: P/E ~5.74x, P/B ~0.39x, P/S ~2.76x.

Income Statement

Metric	Value	YoY Change	QoQ Change
Revenue	68.72M	-16.18%	79.37%
Gross Profit	16.75M	-25.48%	54.33%
Operating Income	9.12M	-29.22%	346.61%
Net Income	8.26M	-22.12%	341.13%
EPS	0.01	-22.03%	342.11%

Key Financial Ratios

Gross Profit Margin

Fair

24.40%

Gross profit margin is moderate, room for improvement in cost management

Operating Profit Margin

Fair

13.30%

Operating margin is moderate, room for improvement in cost management

Net Profit Margin

Good

12.00%

Net profit margin is healthy and competitive within industry standards

Return on Assets

Weak

1.53%

Return on assets suggests inefficient capital allocation

Return on Equity

Weak

1.71%

Return on equity suggests inefficient capital allocation

Current Ratio

Strong

7.20

Current ratio indicates excellent liquidity and financial flexibility

Debt to Equity

Conservative

0.00

Debt-to-equity shows conservative leverage and low financial risk

P/E Ratio

Value

5.74x

P/E ratio suggests potential undervaluation or stable earnings

Price to Book

Undervalued

0.39x

Trading below book value, potential value opportunity or distressed

Historical Earnings Comparison

Period	Revenue ($M)	EPS ($)	YoY Growth	Report
Q2 2025	64.76	0.00	-5.8%	View
Q1 2025	32.38	0.00	-15.5%	View
Q4 2024	68.72	0.01	-57.2%	View
Q3 2024	68.72	0.01	-16.2%	View

Modern Chinese Medicine (1643.HK) Q3 2024 Earnings Report

Company Status Snapshot

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue Trend

Margin Analysis

Financial Highlights

Income Statement

Key Financial Ratios

Management Insights Available for Members

Peer Comparison Available for Members

Investment Outlook & SWOT Available for Members

Historical Earnings Comparison

More 1643.HK Quarterly Reports

1643.HK

1643.HK

1643.HK

Q3 2024 Reports in Healthcare Sector

1601.HK

Related Financial Data

Sector Analysis: Healthcare

1643.HK Full Profile

1643.HK Financial Statements

Earnings Calendar